Professional Documents
Culture Documents
Cancer
Dr. Awad Alqahtani
Md,MSc.FRCSC(G.Surgery)FRCSC(Surgical Oncology)
Laparoscopic and Bariatric Surgery
Outlines
Epidemiology
Commonest endocrine malignancy
o 1% of all malignancies
o 0.5-1 per 100000
Good prognosis
Extent of treatment is hotly debated
o No randomized trials
Genetics:
Family History:
Radiation Exposure:
Age:
Race:
Thyroid Neoplasm
Benign
Malignant
Primary
Follicular
Cells
Secondary
Parafollicular
Cells
Lymphoid
Cells
Medullary
Lymphoma
Differentiated
Undifferentiated
Follicular
Papillary
Hurthle Cell
Anaplastic
Presentation
Important History
Radiation to neck / chest
MEN syndrome
o Family history
o Diarrhoea
o Adrenal tumour
Evaluation
Thyroid profile
Serum Thyroglobulin
Serum Calcitonin
Thyroid scan
o Hot/warm/cold nodule 20% malignant
Serum Ca++
Imaging
o
o
o
o
U/S
C.T
MRI
Scintigraphy
Diagnosis
Laboratory:
o
o
o
o
o
TSH
T3, T4
Serum Thyroglobulin
Serum Thyroid Antibodies
FNA
Laboratory
FNA Cytology
Imaging
U/S is the investigation of choice.
C.T Regional and distant metastases
MRI Limited role in the diagnosis
Useful in detecting cervical LN metastases
Scintigraphy (I-123)
Characterizing funtioning nodules
Staging of follicular and papillary Ca
Prognostic Indicators
AGES score:
Age
Hisological Grade
Extrathyroidal invasion
Metastasis
Distant Metastasis
Age
Completeness of original surgical resection
Extrathyroidal Invasion
Size of original lesion
Management
Medical
Replacement therapy.
Suppression of TSH release. ( recurrence)
Surgical
Treatment of choice.
Extent of resection is still controversial.
Thyroid Surgeries
Ipsilateral lobectomy
Subtotal Thyroidectomy
Near-total Thyroidectomy
Total Thyroidectomy
Papillary Carcinoma
Most common Thyroid carcinoma (80%)
Related to radiation exposure in I-sufficient areas.
Female:male ratio is 2:1
Mean age of presentation is 30 to 40 yrs.
Slow growing painless mass. Euthyroid-status.
LN metastases is common, may be the presenting
symptom (Lateral Aberrant Thyroid).
Distant metastases is uncommon at initial
presentation.
Develop in 20% of cases. (Lungs, liver, bones,brain)
Papillary Carcinoma
FNA biopsy is diagnostic.
Treatment
Follicular Carcinoma
Follicular Carcinoma
Treatment:
Post-operative
Management
Thyroid hormone
o Replacement therapy
o Suppression of TSH release
Thyroglobulin measurement
o
o
o
o
Post-operative
Management
Radioiodine Therapy:
Medullary Carcinoma
Medullary Carcinoma
Diagnosis
Medullary Carcinoma
Treatment:
Medullary Carcinoma
Prophylactic Thyroidectomy in RET mutation
detection
o Before age of 6 yrs for MEN2A
o Before age of 1 yr for MEN2B
Anaplastic Carcinoma
Anaplastic Carcinoma
FNAC is diagnostic.
Treatment:
Other Types
Thyroid Lymphoma:
Hurthle-Cell Carcinoma:
Prognosis
Tumor
Papillary Ca.
Follicular Ca.
Hurthle Cell Ca.
Medullary Ca.
Anaplastic Tumor
Prognosis
74-93% long-term survival
rate
43-94% long-term survival
rate
20% mortality rate at 10 years
80% 10-year survival rate
45% with LN involvement
Median survival of 4 to 5
months at time of diagnosis